Souhaitez-vous accéder aux communiqués récents ?

Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European...

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Peanut Allergy Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" has been added to ResearchAndMarkets.com's...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis.

Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...

Preclinical in vivo efficacy data (PoC) in atopic dermatitis of disease-modifying therapy; positive patent opinion from the EU Patent Office

Washington, DC, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) celebrates the recognition of our Chief Medical Officer, Matthew Greenhawt, MD, MBA, MSc, as the...

Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs)

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "Allergy Shots Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user,...